Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02756572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02756572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2016
Completion date
July 1, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blasts 10 percent or more of bone marrow nucleated cells, chronic myelomonocytic leukemia-2, high grade malignant neoplasm, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts-2, myeloid neoplasm, previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia, refractory acute myeloid leukemia